Bonne Santé Group Signs Joint Venture Agreement with Ultimaxx Health
Agreement Positions Companies for Significant Growth as Bonne Santé Leverages Its Digital Marketing Group and Manufacturing Expertise with Ultimaxx’s LEVARE Brand of Pain Relief Products
Miami, FL – July 19, 2018 – Bonne Santé Group, Inc., an early stage global nutraceutical company, announced today that it has signed an agreement with Ultimaxx, Inc. (d/b/a Ultimaxx Health), the developer of the patented LEVARE® brand of all-natural products, as both companies aim to leverage their unique capabilities and customers in the nutraceutical and health and wellness industry.
The joint venture is focused on the manufacturing, marketing and distribution of a broad array of dietary supplements, primarily under the LEVARE trademark. LEVARE is an all-natural pain relief supplement solution for consumers, developed by orthopedic surgeon Lenny Lomax, M.D., founder of Ultimaxx Health. The joint venture will leverage Bonne Santé’s manufacturing operations in the nutraceutical space, as well as its digital marketing group to sell directly to consumers through a variety of online distribution channels and eCommerce platforms, including: eBay, Google and Amazon.
“We are pleased to announce this milestone joint venture agreement for our company as we embark on this strategic partnership with Ultimaxx Health,” said A.J. Cervantes, Executive Vice Chairman of Bonne Santé. “Utilizing our operational capabilities and digital marketing platform, we are looking forward to working with Dr. Lomax and his team to drive our respective capabilities and expand the innovative LEVARE product line to meet the rapidly increasing demand for more natural alternatives to pain relief across all major markets. Both companies are looking forward to cultivating significant opportunities together as we position ourselves for a global online product launch of LEVARE.”
LEVARE is a patented revolutionary non-narcotic formula that combines 12 specific natural ingredients, each chosen for their unique medicinal characteristics, as well as their inflammation relieving qualities. Most importantly, this proprietary formulation works to synergistically create a powerful, fast-acting, non-habit-forming pain relief supplement, which has been clinically tested and officially entered into the prestigious Natural Medicine / Therapeutic Resources Database.
“I believe our partnership with Bonne Santé Group and its strong management team, led by A.J. Cervantes and William Nicholson, former COO of Amway, represents an extraordinary opportunity for significant growth in this increasingly important market,” stated Lenny Lomax, M.D., President and CEO of Ultimaxx Health. “Now more than ever, the U.S. civilian and military populations are in dire need of non-narcotic, non-habit-forming pain relief alternatives as we face the expanding opioid crisis in America. There are reportedly over 20,000 annual prescription narcotic related overdose deaths in the U.S. alone, outnumbering both heroin and cocaine combined, with one person dying approximately every 19 minutes. Ultimaxx Health is committed to addressing this serious public health epidemic, and we are pleased to partner with Bonne Santé to bring these products to the masses, in both the United States and various international markets around the world.”
It is expected that the joint venture will take advantage of numerous synergies between the two companies, including the manufacturing of the LEVARE product lines through Bonne Santé’s Millenium manufacturing facility, which is a 22,000 sq. foot state-of-the-art FDA-approved facility in South Florida. The location of the facility in Doral, part of the larger Miami metropolitan area, is advantageous due to its close proximity to the Port of Miami, as well as being minutes away from shipping warehouses for some of the largest ecommerce companies in the world, including distribution centers for Amazon, Google and Walmart.
In addition, Bonne Santé’s digital marketing group is expected to provide significant new sales opportunities for LEVARE. This highly-focused team at Bonne Santé represents tech industry veterans with decades of experience in the realm of online marketing and sales, including experience at companies such as AliExpress, Yahoo and Google. The Bonne Santé digital marketing group is also leveraging social media strategies and influencers on Facebook, Instagram and Twitter, as well as leveraging the capacity of Amazon FBA and Walmart.com for true multichannel and multilingual global brand expansion of LEVARE.
More than ever, safe, effective, non-narcotic, non-habit-forming pain relief solutions are needed in order to combat the devastating epidemic of overdose and death relating to opioid abuse. Ultimaxx has validated the safety and efficacy of LEVARE after conducting a clinical trial in 2009. For more detailed information and results of the study for LEVARE, please navigate to: http://levarepainrelief.com/levare-clinical-data
About Ultimaxx Health
Ultimaxx Health, www.ultimaxxhealth.com, a natural nutraceutical company founded in 2009, is the owner of the patented LEVARE® brand of products, an all-natural pain relief supplement solution for consumers. The clinically effective, non-narcotic, pain relief supplement, combines twelve natural herbal ingredients to support general relief of pain naturally. At Ultimaxx Health, the company’s mission is to develop innovative solutions to pressing public health problems, with a key emphasis on resolving the epidemic of prescription painkiller abuse and improving the general health and well-being of humanity by “Changing the World Naturally”.
About Bonne Santé Group, Inc.
Bonne Santé Group, Inc. is engaged in the manufacturing, acquisition, operation and sale of a broad spectrum of nutraceutical and related products. Structured as a global nutraceutical holding company, BSG is executing a buy and build strategy with serial accretive acquisitions. To drive growth and earnings, the Company will develop proprietary products as well as acquire other brands. As part of its online marketing initiatives, the Bonne Santé Digital Marketing Group is being housed in the Company’s Millenium manufacturing facility, leveraging its most recent acquisition of the 22,000 square-foot state-of-the-art facility in Doral, Florida, which is developing a wide variety of nutraceutical products such as vitamins, sports nutrition, and other health supplements. The management team and the board of directors of Bonne Santé have an objective of creating a major international nutraceutical and related products company targeting a minimum of $250 to $500 million in revenues within the first three years following the initial acquisition,
manufacturing, and marketing a wide range of world-class nutraceutical products and next- generation delivery technologies.
Certain matters discussed within this press release are forward-looking statements. Although Bonne Santé Group believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Bonne Santé Group does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Bonne Santé Group will successfully acquire its acquisition targets. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks.
The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure or prevent any disease.
Bonne Santé Group, Inc.
Executive Vice Chairman
Lenny Lomax, M.D.
President and CEO